Design, construction, and in vitro analysis of A33scFv::CDy, a recombinant fusion protein for antibody-directed enzyme prodrug therapy in colon cancer

International Journal of Oncology

Volumn 31, Issue 4, 2007, Pages 951-957

  Coelho, Vânia ^a   Dernedde, Jens ^b   Petrausch, Ulf ^a   Panjideh, Hossein ^b   Fuchs, Hendrik ^b   Menzel, Christoph ^c   Dübel, Stefan ^c   Keilholz, Ulrich ^a   Thiel, Eckhard ^a   Deckert, P Markus ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Inst F Klin Chem Pathobiochemie   (Germany)

^c TECHNICAL UNIVERSITY OF BRAUNSCHWEIG   (Germany)

Author keywords

A33 antibody; Antibody directed enzyme prodrug therapy; Colon carcinoma; Recombinant fusion proteins; Tumor targeting

Indexed keywords

CYTOSINE DEAMINASE; FLUCYTOSINE; FLUOROURACIL; GPA33 PROTEIN, HUMAN; HYBRID PROTEIN; IMMUNOGLOBULIN FRAGMENT; MEMBRANE PROTEIN; MONOCLONAL ANTIBODY; PRODRUG; UNCLASSIFIED DRUG;

AFFINITY CHROMATOGRAPHY; ANTIBODY SPECIFICITY; ARTICLE; CELL CULTURE; COLON TUMOR; ENZYMOLOGY; FLOW CYTOMETRY; GENE FUSION; GENETICS; HUMAN; IMMUNOLOGY; METABOLISM; MOLECULAR CLONING; PATHOLOGY; PICHIA; PROTEIN ENGINEERING;

ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; ARTIFICIAL GENE FUSION; CHROMATOGRAPHY, AFFINITY; CLONING, MOLECULAR; COLONIC NEOPLASMS; CYTOSINE DEAMINASE; FLOW CYTOMETRY; FLUCYTOSINE; FLUOROURACIL; HUMANS; IMMUNOGLOBULIN FRAGMENTS; MEMBRANE GLYCOPROTEINS; PICHIA; PRODRUGS; PROTEIN ENGINEERING; RECOMBINANT FUSION PROTEINS; TUMOR CELLS, CULTURED;

EID: 35848952531     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.31.4.951     Document Type: Article

References (24)

1. Yokota T, Milenic DE, Whitlow M and Schlom J: Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. Cancer Res 52: 3402-3408, 1992.
2. Begent RH, Verhaar MJ, Chester KA, Casey JL, Green AJ, Napier MP, Hope-Stone LD, Cushen N, Keep PA, Johnson CJ, Hawkins RE, Hilson AJ and Robson L: Clinical evidence of efficient tumor targeting based on single-chain Fv antibody selected from a combinatorial library. Nat Med 2: 979-984, 1996.
3. Napier MP, Sharma SK, Springer CJ, Bagshawe KD, Green AJ, Martin J, Stribbling SM, Cushen N, O'Malley D and Begent RH: Antibody-directed enzyme prodrug therapy: efficacy and mechanism of action in colorectal carcinoma. Clin Cancer Res 6: 765-772, 2000.
4. Bagshawe KD: Antibody-directed enzyme prodrug therapy for cancer: its theoretical basis and application. Mol Med Today 1: 424-431, 1995.
5. Senter PD and Springer CJ: Selective activation of anticancer prodrugs by monoclonal antibody-enzyme conjugates. Adv Drug Deliv Rev 53: 247-264, 2001.
6. Sharma SK, Bagshawe KD, Springer CJ, Burke PJ, Rogers GT, Boden JA, Antoniw P, Melton RG and Sherwood RF: Antibody directed enzyme prodrug therapy (ADEPT): a three phase system. Dis Markers 9: 225-231, 1991.
7. Springer CJ, Bagshawe KD, Sharma SK, Searle F, Boden JA, Antoniw P, Burke PJ, Rogers GT, Sherwood RF and Melton RG: Ablation of human choriocarcinoma xenografts in nude mice by antibody-directed enzyme prodrug therapy (ADEPT) with three novel compounds. Eur J Cancer 27: 1361-1366, 1991.
8. Eccles SA, Court WJ, Box GA, Dean CJ, Melton RG and Springer CJ: Regression of established breast carcinoma xenografts with antibody-directed enzyme prodrug therapy against c-erbB2 p185. Cancer Res 54: 5171-5177, 1994.
9. Wallace PM, MacMaster JF, Smith VF, Kerr DE, Senter PD and Cosand WL: Intratumoral generation of 5-fluorouracil mediated by an antibody-cytosine deaminase conjugate in combination with 5-fluorocytosine. Cancer Res 54: 2719-2723, 1994.
10. Martin J, Stribbling SM, Poon GK, Begent RH, Napier M, Sharma SK and Springer CJ: Antibody-directed enzyme prodrug therapy: pharmacokinetics and plasma levels of prodrug and drug in a phase I clinical trial. Cancer Chemother Pharmacol 40: 189-201, 1997. (Pubitemid 27257731)
11. Powers DB, Amersdorfer P, Poul M, Nielsen UB, Shalaby MR, Adams GP, Weiner LM and Marks JD: Expression of single-chain Fv-Fc fusions in Pichia pastoris. J Immunol Methods 251: 123-135, 2001.
12. Fischer R, Drossard J, Emans N, Commandeur U and Hellwig S: Towards molecular farming in the future: pichia pastoris-based production of single-chain antibody fragments. Biotechnol Appl Biochem 30: 117-120, 1999.
13. Sakamoto J, Kojima H, Kato J, Hamashima H and Suzuki H: Organ-specific expression of the intestinal epithelium-related antigen A33, a cell surface target for antibody-based imaging and treatment in gastrointestinal cancer. Cancer Chemother Pharmacol 46 (Suppl.): S27-S32, 2000.
14. Scott AM, Lee FT, Jones R, Hopkins W, MacGregor D, Cebon JS, Hannah A, Chong GUP, Papenfuss A, Rigopoulos A, Sturrock S, Murphy R, Wirth V, Murone C, Smyth FE, Knight S, Welt S, Ritter G, Richards E, Nice EC, Burgess AW and Old LJ: A phase I trial of humanized monoclonal antibody A33 in patients with colorectal carcinoma: biodistribution, pharmacokinetics, and quantitative tumor uptake. Clin Cancer Res 11: 4810-4817, 2005.
15. Deckert PM, Renner C, Cohen LS, Jungbluth A, Ritter G, Bertino JR, Old LJ and Welt S: A33scFv-cytosine deaminase: a recombinant protein construct for antibody-directed enzyme-prodrug therapy. Br J Cancer 88: 937-939, 2003.
16. Rader C, Ritter G, Nathan S, Elia M, Gout I, Jungbluth AA, Cohen LS, Welt S, Old LJ and Barbas CF III: The rabbit antibody repertoire as a novel source for the generation of therapeutic human antibodies. J Biol Chem 275: 13668-1376, 2000. (Pubitemid 30257436)
17. Invitrogen. A Manual of Methods for Expression of Recombinant Proteins in Pichia pastoris. http://www.invitrogen.com/content/sfs/manuals/pich-man.pdf [Catalog no K1710-01]. 1-11-2002.
18. Nygren P, Fridborg H, Csoka K, Sundstrom C, De La TM, Kristensen J, Bergh J, Hagberg H, Glimelius B and Rastad J: Detection of tumor-specific cytotoxic drug activity in vitro using the fluorometric microculture cytotoxicity assay and primary cultures of tumor cells from patients. Int J Cancer 56: 715-720, 1994. (Pubitemid 24086775)
19. Heath JK, White SJ, Johnstone CN, Catimel B, Simpson RJ, Moritz RL, Tu GF, Ji H, Whitehead RH, Groenen LC, Scott AM, Ritter G, Cohen L, Welt S, Old LJ, Nice EC and Burgess AW: The human A33 antigen is a transmembrane glycoprotein and a novel member of the immunoglobulin superfamily. Proc Natl Acad Sci USA 94: 469-474, 1997.
20. Pennell CA and Eldin P: In vitro production of recombinant antibody fragments in Pichia pastoris. Res Immunol 149: 599-603, 1998.
21. Macauley-Patrick S, Fazenda ML, McNeil B and Harvey LM: Heterologous protein production using the Pichia pastoris expression system. Yeast 22: 249-270, 2005.
22. Daly R and Hearn MT: Expression of heterologous proteins in Pichia pastoris: a useful experimental tool in protein engineering and production. J Mol Recognit 18: 119-138, 2005.
23. Kievit E, Bershad E, Ng E, Sethna P, Dev I, Lawrence TS and Rehemtulla A: Superiority of yeast over bacterial cytosine deaminase for enzyme/prodrug gene therapy in colon cancer xenografts. Cancer Res 59: 1417-1421, 1999.
24. Ireton GC, Black ME and Stoddard BL: The 1.14 A crystal structure of yeast cytosine deaminase: evolution of nucleotide salvage enzymes and implications for genetic chemotherapy. Structure 11: 961-972, 2003.